Robert Lisicki
Chief Executive Officer presso ZURA BIO LIMITED
Patrimonio netto: - $ in data 31/03/2024
Profilo
Mr. Robert Lisicki is a Chief Executive Officer & Director at Zura Bio Ltd.
He is on the Board of Directors at Zura Bio Ltd., Adiso Therapeutics, Inc. and Cadrenal Therapeutics, Inc. Mr. Lisicki was previously employed as a Chief Executive Officer & Director by InCarda Therapeutics, Inc., a Chief Commercial Officer & Executive VP by Arena Pharmaceuticals, Inc., a Chief Customer Officer, SVP-Sales & Marketing by Daiichi Sankyo, Inc., a Vice President & General Manager by Amgen, Inc., and a General Manager & Vice President-Cardio Metabolic by Regeneron Pharmaceuticals, Inc. He received his undergraduate degree from State University of New York at Albany.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
07/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Robert Lisicki
Società | Posizione | Inizio |
---|---|---|
CADRENAL THERAPEUTICS, INC. | Director/Board Member | 23/07/2023 |
ZURA BIO LIMITED | Chief Executive Officer | 08/04/2024 |
Adiso Therapeutics, Inc.
Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Director/Board Member | 12/10/2023 |
Precedenti posizioni note di Robert Lisicki
Società | Posizione | Fine |
---|---|---|
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Chief Executive Officer | 01/03/2023 |
ARENA PHARMACEUTICALS | Corporate Officer/Principal | 01/03/2022 |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Sales & Marketing | 01/04/2018 |
AMGEN INC. | Corporate Officer/Principal | - |
REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Robert Lisicki
State University of New York at Albany | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
AMGEN INC. | Health Technology |
REGENERON PHARMACEUTICALS, INC. | Health Technology |
ZURA BIO LIMITED | Health Technology |
CADRENAL THERAPEUTICS, INC. | Health Technology |
Aziende private | 4 |
---|---|
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Health Technology |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Health Technology |
Adiso Therapeutics, Inc.
Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Health Technology |
- Borsa valori
- Insiders
- Robert Lisicki